Heron Therapeutics
HRTX
102 hedge funds and large institutions have $1.06B invested in Heron Therapeutics in 2015 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 19 reducing their positions, and 13 closing their positions.
202% more call options, than puts
Call options by funds: $127M | Put options by funds: $41.9M
126% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 19
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
16% more funds holding
Funds holding: 88 → 102 (+14)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less capital invested
Capital invested by funds: $1.13B → $1.06B (-$61M)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$119M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$75.6M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$40.9M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$38.4M |
| 5 |
Goldman Sachs
New York
|
+$24M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$23.7M |
| 2 |
BC
Broadfin Capital
New York
|
-$17.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$17.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$14M |
HRTX Hedge Fund Activity: Q3 2015 in Review
102 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2015, worth a combined $1.06B — down 5.4% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new HRTX positions and 13 closed out — a net gain of 15 holders — while 43 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $119M. The largest seller was Millennium Management, exiting entirely with an estimated $23.7M sold.
- 102 institutional investors held Heron Therapeutics (HRTX) as of Q3 2015, up from 88 in Q2 2015.
- Funds reported $1.06B of Heron Therapeutics stock for Q3 2015, down 5.4% quarter-over-quarter.
- 28 funds opened new Heron Therapeutics positions in Q3 2015 and 13 closed out, a net change of +15 holders.
- The largest Heron Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $119M added.
- The largest Heron Therapeutics seller in Q3 2015 was Millennium Management, an estimated $23.7M sold.
Based on aggregated 13F filings for Q3 2015.